KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras

First came doubts about the combinability of Amgen’s Lumakras with a standard PD-1 inhibitor. Now, the company will need to defend its first-in-class KRAS inhibitor at an upcoming advisory committee meeting.